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Abstract
Chronic hyperglycemia induces insulin resistance by mechanisms that are incompletely understood. One model of
hyperglycemia-induced insulin resistance involves chronic preincubation of adipocytes in the presence of high glucose and
low insulin concentrations. We have previously shown that the mTOR complex 1 (mTORC1) plays a partial role in the
development of insulin resistance in this model. Here, we demonstrate that treatment with Go-6976, a widely used
‘‘specific’’ inhibitor of cPKCs, alleviates hyperglycemia-induced insulin resistance. However, the effects of mTOR inhibitor,
rapamycin and Go-6976 were not additive and only rapamycin restored impaired insulin-stimulated AKT activation.
Although, PKCa, (but not –b) was abundantly expressed in these adipocytes, our studies indicate cPKCs do not play a major
role in causing insulin-resistance in this model. There was no evidence of changes in the expression or phosphorylation of
PKCa, and PKCa knock-down did not prevent the reduction of insulin-stimulated glucose transport. This was also consistent
with lack of IRS-1 phosphorylation on Ser-24 in hyperglycemia-induced insulin-resistant adipocytes. Treatment with Go-
6976 did inhibit a component of the mTORC1 pathway, as evidenced by decreased phosphorylation of S6 ribosomal
protein. Raptor knock-down enhanced the effect of insulin on glucose transport in insulin resistant adipocytes. Go-6976 had
the same effect in control cells, but was ineffective in cells with Raptor knock-down. Taken together these findings suggest
that Go-6976 exerts its effect in alleviating hyperglycemia-induced insulin-resistance independently of cPKC inhibition and
may target components of the mTORC1 signaling pathway.
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Introduction
Insulin resistance is a common pathological condition defined as
the reduced ability of insulin to produce its biological effects.
Clinically, it refers to the reduced effectiveness of insulin to lower
plasma glucose. Insulin resistance is a major feature of Type 2
diabetes and is commonly associated with numerous other
conditions, e.g. obesity, the metabolic syndrome, polycystic ovary
syndrome, glucocorticoid excess, etc. The molecular basis of
insulin resistance is currently incompletely understood, but in each
of these conditions is likely to be multi-factorial, being induced by
glucotoxicity, lipotoxicity, and hormones. In contrast, the insulin
resistance that accompanies uncontrolled Type 1 diabetes is
primarily attributed to glucotoxicity and is reversible with insulin
therapy in vivo [1,2]. However, the mechanistic basis of
hypergylcemia-induced insulin resistance is controversial. Its
expression appears to be tissue/cell-type specific and may differ
from that caused by lipotoxicity.
We have studied the mechanism(s) of insulin resistance in an in
vitro model of glucotoxicity in 3T3-L1 adipocytes in some detail
[3,4]. This represents a model of ‘fasting hyperglycemia-induced
insulin resistance’ as is observed in diabetes. Under control
conditions (i.e. after incubation in 5 mM glucose), adipocytes are
exquisitely insulin responsive - as assessed by the insulin stimulated
glucose uptake. Chronic preincubation in either high glucose
(25 mM) or in the presence of a relatively low dose of insulin
(0.6 nM) alone does not alter the insulin-stimulated response.
However, chronic preincubation with both high glucose and low
insulin causes a 40–60% impairment of subsequent insulin-
stimulated glucose transport. This state of insulin resistance is
not accompanied by changes in the expression of the glucose
transporters, GLUT1 and GLUT4 and the proximal insulin
signaling cascade appears to be intact, as judged by the insulin
response of insulin receptor substrate-1 (IRS-1)-bound phospha-
tidylinositol (PI) 3-kinase activity [3]. However, in this model there
is a block downstream of PI3-kinase activation, which is
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manifested by markedly impaired activation of protein kinase B/
Akt [5].
Since we had evidence that flux through the hexosamine
synthesis pathway was increased by exposure to high glucose, we
explored the possibility that the insulin resistance reflected
enhanced O-GlcNAc modification of some regulatory proteins.
However, increased expression of the enzyme which removes O-
GlcNAc from proteins or .90% knock-down of O-GlcNAc
transferase did not affect the development of insulin resistance in
our model, suggesting that other pathways certainly played a role
[6]. Similarly, we found no evidence to suggest that enhanced
superoxide production caused the insulin resistance in this model
[7].
We discovered that basal PtdIns(3,4,5)P3 was unaltered in
control and insulin resistant cells, however, following insulin
stimulation, the response was diminished by 34% in the latter.
Concomitantly, the amount of PTEN protein, a lipid phosphatase,
which dephosphorylates PtdIns(3,4,5)P3 in the 3-position was
significantly and specifically increased in the insulin resistant cells.
Treatment with rapamycin, a specific inhibitor of mTORC1,
inhibited increased PTEN expression and partially restored
insulin-stimulated glucose transport and Akt activation to the
insulin resistant cells. Thus, we have evidence that at least one
mechanism, which causes insulin resistance in our model, involves
the mTOR pathway [7].
Given that blocking mTORC1 restored the insulin resistance
only partially, we continued the search for other pathways, which
may be involved. Protein kinase C (PKC) seemed to be a logical
candidate, particularly because it is known to be activated under
some conditions by exposure to high glucose [8]. This hypothesis
was supported by initial experiments, which showed that treating
cells with Go-6976 partially prevented the development of insulin
resistance in cells, which had been pretreated with high glucose
and low dose insulin. Go-6976 is a widely used inhibitor of PKC,
which is relatively selective for the conventional PKC isoforms,
(cPKC a and b) and has much less affinity for the novel and
atypical PKC-s. PKCb is not expressed in NIH/hIR cells (mouse
fibroblasts overexpressing the human insulin receptor) [9], and we
were unable to detect it by immunoblotting in murine 3T3-L1
adipocytes, which are also fibroblast derived. PKCa was
abundantly expressed in our cells, suggesting that we may have
identified a candidate, which would be partially responsible for the
development of glucose/insulin mediated insulin resistance.
However, Go-6976 can also inhibit other enzymes including S6-
kinase 1 [10], a substrate of mTORC1. It is also a potent in vivo
inhibitor of protein kinase D (PKD) [11,12]. The experiments
described here led us to the conclusion that PKCa may not be
involved in causing hyperglycemia-induced insulin resistance in
adipocytes, and that at least some of the effects caused by Go-6976
may have been mediated via its inhibition of the mTORC1
pathway.
Research Design and Methods
Cell culture and glucose transport assay
3T3-L1 fibroblasts (ATCC 2001; cat #CL-173) were differen-
tiated into adipocytes as previously described [3]. Cells were
studied on days 8–12 from the initiation of the differentiation
protocol, when .95% of the cells exhibited the adipocyte
phenotype. They were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) containing 25 mM glucose and 10% fetal
bovine serum (FBS). Before experiments the cells were exposed for
18 h to DMEM containing 1% FBS and either 5 mM or 25 mM
glucose, with or without 0.6 nM insulin, as indicated. They were
then serum and insulin deprived for 2 h, and after washing placed
into Krebs Ringer bicarbonate/HEPES (KRBH) buffer without
glucose for 10 min and then incubated with or without a
maximally stimulating insulin dose (100 nM) for 15 min [3].
Glucose transport was assessed as the uptake of 2-deoxy-D-glucose
(2-DOG) for 3 min as described [3] and normalized to protein
concentration assessed using the Coomassie Protein Reagent
(Pierce). In some experiments activators and/or inhibitors of PKC
were added to the media before assay. The activator used was
phorbol 12-myristate 13-acetate (PMA) (Calbiochem), the inhib-
itors used were Go-6976, a cell permeable inhibitor of PKC, which
selectively inhibits PKCa and b1 isozymes, at nM concentrations,
but does not affect the kinase activities of Ca2+ independent
isozymes, d, e and f, even at mM concentrations (Cat.
No. 365250), and bisindolylmaleimide I, Go-6850, which is a
broader PKC inhibitor (Cat. No. 203290, both from Calbiochem).
We also tested Ruboxistaurin (LY379196), kindly provided by
Lilly Research Laboratories, which at the doses used (300 nM) is a
highly selective inhibitor of PKCb [8,13].
RNAi
To test the role of PKCa, PKCl and mTORC1 pathway in our
model of insulin resistance we investigated the effect of reducing
their expression via transfection of mouse specific small interfering
siRNA-s. We purchased SMARTpool reagents from Dharmacon
against PKCa, PKCl and against Raptor, each consist of a
mixture of 4 unique siRNA-s developed against the targeted gene
and are guaranteed to silence the RNA by.75%. For cells treated
with non-targeting siRNA, we used Dharmacon’s non-targeting
siRNA pool of 4.
3T3-L1 adipocytes are notoriously difficult to transfect and until
recently their successful siRNA transfection usually involved
electroporation [14]. Recently, a technology using virus derived
amphipatic peptides has been developed, that directly interact
with nucleic acid cargos to form nanoparticles, which diffuse
through plasma membranes and release their cargos inside the cell
[15]. The technology has been adapted by the manufacturer
(Panomics, Fremont, CA) to several cell lines, including 3T3-L1
adipocytes. We adopted the following protocol for transfection of
the latter [6]. On day 6 after initiation of the differentiation
protocol, cells were subcultured to a density of 2.56104 cells/cm2
and incubated overnight in DME containing 25 mM glucose and
10% FBS. Then FBS was removed and cells were washed with
PBS and transfected with a final concentration of 40 nM non-
targeting or targeting siRNA using the DeliverX Plus Kit
(Panomics). Following 4 h incubation with the siRNA, FBS was
added to a concentration of 10% and cells were incubated for an
additional 18 h. Media was replaced with fresh DME containing
25 mM glucose and 10% FBS for 24 h. Cells were then incubated
for 18 h in DME containing 1% FBS and 5 mM glucose or
25 mM glucose+0.6 nM insulin, with or without Go-6976 or
rapamycin, then serum- and insulin-deprived for 2 h and glucose
transport measured as described. The degree of knock-down was
assessed by Western blotting for the respective protein.
Western blots
Total post-nuclear cell lysates were prepared in lysis buffer as
previously described [3,6]. Cell extracts were separated on 7% or
12% SDS-PAGE and transferred to nitrocellulose. They were
blocked for 1 h and then incubated overnight in blocking buffer
containing one of the following: rabbit P-PKC a/b (Thr 638/641)
antibody, P-Akt (Ser473) antibody, rabbit P-p70 S6kinase (Thr
389) antibody, rabbit P-S6 ribosomal protein (Ser 240/244)
antibody or rabbit anti-Raptor antibody (all 1:1000, each from
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Cell Signaling). Following washing, membranes were incubated in
goat anti-rabbit IgG (1:10,000, Jackson Immunoresearch) for 1 h,
washed, developed with West Pico ECL Reagent (Pierce), exposed
to film, and quantified by laser densitometry using a National
Institute of Health Image Analyzer Program. Membranes that had
been exposed to P-PKC a/b2 antibody were stripped and
reanalyzed with an antibody to PKCa (1:1000, Cell Signaling);
while blots developed with anti-phospho- p70 S6kinase or with
anti-phospho S6 ribosomal protein antibody were stripped and
analyzed with mouse p70 S6kinase antibody (1:200, Santa Cruz)
or with rabbit anti-S6 ribosomal protein antibody (1:1000, Cell
Signaling), respectively. Finally, most gels were stripped and
analyzed with rabbit b-tubulin antibody (1:200, Santa Cruz) to
document equal loading of the gel.
In some experiments the phosphorylation of Ser 24 of IRS-1
was tested, because this site is directly responsive to stimulation by
PKCa [9]. The preparation of this antibody has been described
[9]. Total post-nuclear cell lysates (1 mg protein) were immuno-
precipitated with 2 mg of rabbit anti-IRS-1 antibody (Upstate/
Chemicon) overnight at 4uC. Immunocomplexes were collected
for 2 h with protein G Sepharose, washed and eluted with
Laemmli’s sample buffer for 10 min at 95uC. The eluates were
separated by SDS-PAGE and exposed to P-IRS-1 (Ser 24) rabbit
antibody, at a dilution of 1:100 overnight at 4uC. Subsequent
development with goat anti-rabbit IgG was as described above.
Results and Discussion
Go-6976 treatment enhances insulin-sensitivity in
cultured adipocytes
To generate hyperglycemia- and insulin-induced insulin resis-
tant (GI-IR) adipocytes, 3T3-L1 adipocytes were preincubated for
18 h in culture media containing 25 mM glucose and supple-
mented with 0.6 nM insulin. In contrast, control ‘insulin-sensitive’
adipocytes (IS) were generated by preincubation with 5 mM
glucose without insulin supplementation. Insulin-stimulated glu-
cose uptake was then determined as detailed in materials and
methods. As previously reported, preincubation in high glucose
Figure 1. Treatment with Go-6976, reverses hyperglycemia-induced insulin resistance in adipocytes. A. Effect of Go-6976 on Glucose
transport. Insulin sensitive (IS) Adipocytes were preincubated in 5 mM glucose while Glucose-induced insulin resistant, (GI-IR) were generated by
preincubation in 25 mM glucose+0.6 nM insulin for 18 h. During serum and insulin deprivation for 2 h, adipocytes were received 0.3 mM Go-6976 or
vehicle control during the last hour of incubation. Glucose (2DOG) uptake was determined in unstimulated (open bars, basal) or in insulin-stimulated
(100 nM for 15 min; filled bars, Insulin) cells. B. Effect of Go-6976 on insulin-stimulated Akt phosphorylation. Adipocytes were treated as in A,
following acute insulin stimulation, cell lysates were collected and both phospho-Akt and total AKT was measured. Quantification represents ratios of
phosphoAKT/Total AKT protein expressed relative to ratios obtained in from control insulin sensitive (IS) adipocytes. C. The effects of rapamycin and
Go-6976 on insulin-stimulated glucose transport. Adipocytes were treated as in A, except that only cells, which have been acutely stimulated with
insulin, are shown. Go-6976 (0.3 mM) and rapamycin (100 nM) are added during the last hour of incubation. D. The effects of rapamycin and Go-6976
on insulin-stimulated Akt phosphorylation. Adipocytes were treated as in C, following acute insulin stimulation, cell lysates were collected and both
phospho-Akt and total AKT was measured. Quantification represents ratios of phosphoAKT/Total AKT protein expressed relative to ratios obtained in
from control insulin sensitive (IS) adipocytes. Statistical significance is indicated by *p,0.05, and ** = p,0.005 compared to controls with the same
preincubation.
doi:10.1371/journal.pone.0108963.g001
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together with low dose insulin inhibited insulin-stimulated (p,
0.001) glucose transport (Fig. 1A) confirming that these GI-IR
adipocytes were indeed insulin resistant. To identify potential
serine kinases that may be involved in mediating this insulin
resistance and amenable to pharmacological intervention, we
screened a number of kinase inhibitors. Amongst these, Go-6976
was identified as an inhibitor of cPKC isoforms [9] that
significantly enhanced insulin-stimulated glucose transport both
in the GI-IR adipocytes (by 114%, p,0.001) as well in IS
adipocytes (by 23%, p,0.05). Although Go-6976 did not
completely restore insulin stimulated glucose transport to control
levels (p,0.04), the effects only required incubation with 0.3 mM
inhibitor for 1 h immediately following the pretreatment and
preceding determination of insulin sensitivity.
We have previously shown that the insulin resistance that
develops in this model is associated with a marked inhibition of
insulin-stimulated Akt activation [5,7] and this was again observed
in these experiments (Fig. 1B). However, Go-6976 treatment did
not restore insulin-stimulated Akt activation, suggesting that the
target of Go-6976 action is either downstream of, or occurs
parallel to, Akt activation. This observation contrasts with our
previous study in which exposure of GI-IR adipocytes for one hour
to the mTOR inhibitor, rapamycin, partially restored the insulin
resistant glucose transport, and simultaneously corrected the
impaired activation of Akt [7]. To establish whether the effects
of both serine kinase inhibitors (Go-6976 and rapamycin) on
glucose transport were of equal magnitude, additive and/or
synergistic, we performed additional parallel experiments. In this
study there were no significant effects in control insulin sensitive
(IS) adipocytes (Fig. 1C). However, in GI-IR adipocytes, insulin-
stimulated glucose transport was decreased by ,60%. This was
significantly reversed both by rapamycin and Go-6976 treatments
when used individually, however, there was no evidence of any
additive effect when these inhibitors were combined (Fig. 1C)
suggesting that they may target the same pathway. Notably, insulin
resistance was again not completely restored and insulin-stimulat-
ed AKT phosphorylation was also not restored with Go-6976
alone or combination with rapamycin (Fig. 1D).
GI-IR adipocytes do not exhibit enhanced IRS-1
phosphorylation on Ser-24
We recently reported that protein kinase C activators such as
phorbol esters can promote insulin resistance through phosphor-
ylation of Serine-24 on IRS-1 and that this was also inhibited by
Go-6976 [9]. We therefore next investigated whether IRS-1
phosphorylation on Ser-24 was enhanced in GI-IR adipocytes.
Figure 2A shows that 1 mM PMA can induce phosphorylation of
IRS-1 on Ser-24 in IS adipocytes and this coincided with a
mobility shift in total IRS-1 (Fig. 2B). Inclusion of Go-6976
(1 mM) with the PMA reduced both Ser-24 phosphorylation of
IRS1 and the reduction in total IRS-1 mobility (Fig. 2A and 2B).
This is consistent with similar findings reported for NIH3T3 cells
[9]. However, in GI-IR adipocytes, basal IRS-1 Ser-24 phosphor-
ylation was unaltered and the response to PMA with or without
Go-6976 was similar to IS adipocytes. Figure 2C also shows that
acute stimulation with insulin alone (100 nM, 15 min) also did not
induce Ser-24 phosphorylation in the control (IS) or in the insulin
resistant (GI-IR) adipocytes. However, acute insulin was sufficient
to induce a mobility shift in total IRS-1 at least in IS adipocytes
(Fig. 2D). These data suggest that PKCa-mediated phosphoryla-
Figure 2. Hyperglycemia-induced insulin resistance does not promote pSer24 IRS-1, a target of cPKC. Adipocytes were preincubated for
18 h in 5 mM glucose (IS) or in 25 mM glucose+0.6 nM insulin (GI-IR). A and B. During the last hour, cells were exposed to either vehicle control (C),
PMA (1 mM), Go-6976 (1 mM) or both. IRS-1 was immunoprecipitated from subsequent cell extracts and following gel separation western blotted
with an anti-pSer 24 IRS1 (A) or anti-IRS1 (B), as described in Methods. C. pSer 24 IRS1 levels are unaffected by preincubation treatment and acute
insulin stimulation. D. Total IRS1 protein exhibit a mobility shift following acute stimulation with 100 nM insulin for 15 min. All gels are representative
of 3 similar experiments.
doi:10.1371/journal.pone.0108963.g002
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tion of Ser24 on IRS-1 is not involved in hyperglycemia-induced
insulin resistance.
GI-IR adipocytes do not exhibit altered PKCa expression
or activating phosphorylation
Since Go-6976 is widely reported to be an inhibitor of cPKCs
(PKCa/b), and cPKCs have themselves been implicated in other
models of insulin resistance, we next investigated their presence
and putative regulation in GI-IR adipocytes. We were unable to
detect PKCb expression in our cells (data not shown). However,
PKCa protein was detected, as was pThr638/641- PKCa, an
indicator of active PKCa levels (Fig. 3 and Fig. S1). Important-
ly, neither the preincubation conditions (low glucose versus high
glucose plus low dose insulin) nor acute stimulation with high dose
insulin affected either the total amount or the phosphorylation of
PKCa significantly (Fig. 3 and Fig. S1), suggesting that PKCa is
not involved in this model of insulin-resistance. However, the
addition of Go-6976 significantly reduced the expression of PKCa
(Fig. 3B, p,0.001). Nonetheless, there was no difference in the
effect of Go-6976 between IS adipocytes (preincubated in 5 mM
glucose) and GI-IR adipocytes. The effect of Go-6976 on the
phosphorylation of PKCa showed the same trend as that of total
PKCa expression. Although the effect was less pronounced, it was
significant by analysis of variance (p,0.01). In contrast, incubation
of adipocytes for two hours with 1 mM PMA markedly reduced the
expression and phosphorylation of PKCa (Fig. 3, p,0.001). The
ratio of phospho-PKC:Total PKCa was not significantly affected
suggesting that PMA-stimulated effects involved primarily PKCa
degradation. Indeed it is well known that sustained exposure to
PMA promotes activation followed by degradation of cPKC [9].
Addition of Go-6976 or bisindolylmaleimide I for 1 hour to PMA
pretreated cells did not change the PMA effect. The surprising lack
of effect of the PKC inhibitors likely reflects the fact that
adipocytes were first treated with PMA for 1 hr followed by a
further 1 hr with inhibitors (Go-6976 or of bisindolylmaleimide I)
together with PMA. An alternative commonly used albeit
preventative approach, would have been to pretreat adipocytes
with these inhibitors prior to and during PMA exposure. This
approach may have yielded different results with respect to the
effects of PMA.
Figure 3. Phosphorylated PKCalpha and total PKCalpha are not altered by hyperglycemia-induced insulin resistance. Adipocytes
were preincubated for 18 h in 5 mM glucose (IS) or in 25 mM glucose+0.6 nM insulin (GI-IR). During the last 2 hours cells were exposed to either
vehicle control or PMA (1 mM), or during the last hour with Go-6976 (1 mM, Go) or bis-indolylmaleimide (1 mM, Bis). Acute insulin stimulation (black
bars) or non-stimulation (white bars) were performed for 15 min with or without 100 nM insulin. Cells were lysed, proteins extracted and subjected to
western blotting with antibodies to either phosphorylated pThr638/641 PKCalpha/beta (A) or to Total PKCalpha (B). Quantification was determined
as described in Methods. The graph data represents means +/2 SE of 6 observations.
doi:10.1371/journal.pone.0108963.g003
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PKCa knock-down does not alter insulin resistance in
GI-IR adipocytes
To further assess the role of PKCa, we tested the effect of its
knock-down on the development of insulin resistance in our
model. Cells transfected with siRNA against PKCa were
compared to cells transfected with non-targeting RNA and tested
72 h after transfection. PKCa expression at this time was reduced
by 75–78% as judged by Western blots (Fig. 4A). As shown in
Fig. 4B, glucose transport and the development of insulin
resistance were not affected by the PKCa knock-down in either
IS or GI-IR adipocytes. To further assess whether PKCa knock-
down had any effect on insulin-stimulated glucose transport, we
compared the effects of PMA and Go-6976, in the presence or
absence of insulin on glucose transport in IS adipocytes (Fig. 4C).
PMA (1 mM, 1 h) stimulated glucose transport (.2-fold over basal)
in both the PKCa knock-down and the non-targeted controls and
the addition of Go-6976 to PMA partially blocked this effect. The
only significant difference between the PKCa knock-down and the
non-targeting controls was that in the latter PMA inhibited
maximally insulin-stimulated glucose transport by ,17% (p,
0.005) while this did not occur in the PKCa knock-down cells. The
data suggests that while PKCa does play a role in the effect of
PMA on glucose transport in these cells, confirming previous
observations [16], it does not seem to participate, in the
development of hyperglycemia-induced insulin resistance in GI-
IR adipocytes.
PKCb inhibition does not reverse insulin resistance in
GI-IR adipocytes
Although we had no evidence that PKCb is expressed in our
3T3-L1 adipocytes, we also tested whether incubation with a
specific inhibitor of this isoform would alter the insulin resistant
glucose transport in our experiments. Ruboxistaurin had no effect
on glucose transport under any of the conditions tested and failed
Figure 4. PKCalpha knock-down does not prevent the development of hyperglycemia-induced insulin resistance. A. The expression
of PKCalpha is reduced (by 75–78%) in adipocytes treated with anti-PKCalpha siRNA compared with cells infected with non-targeting (NT) siRNA. B.
Experiment designed was as described for Fig. 1 except cells were treated with indicated siRNA prior to glucose uptake determination. C. PMA-
induced insulin resistance is lost in cells infected with anti-PKCalpha siRNA. Adipocytes were infected with non-targeting or with anti-PKCalpha siRNA,
then treated with or without PMA (1 mM, 1 h) followed by acute insulin stimulation and glucose uptake determined. Statistical significance is
indicated by *p,0.005 vs. no PMA.
doi:10.1371/journal.pone.0108963.g004
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to affect the insulin response of glucose transport (n = 5, from two
experiments, Fig. S2).
Effect of PKCl knock-down on insulin-stimulated glucose
transport
In view of the elegant demonstration that atypical PKC’s are
required for insulin-stimulated glucose transport in 3T3-L1
adipocytes [17] we also investigated the role of PKCl (the a-
PKC expressed in adipocytes) in our model. PKCl expression was
decreased by 84% in cells transfected with mouse specific small
interfering si-RNA against PKCl (Fig. 5A). In cells incubated in
5 mM glucose the insulin effect on glucose transport was
decreased by 20% in RNAi treated adipocytes (Fig. 5B, p,
0.001) compared to cells treated with a non-targeting RNA. Our
data qualitatively reproduces previously published observations
[17]. However, it is of interest, that in GI-IR adipocytes, knock-
down of PKCl had no additional inhibitory effect.
Go-6976 affects the phosphorylation of S6 ribosomal
protein
In view of the above findings we next investigated whether Go-
6976 may reverse the development of insulin resistance by
inhibiting enzyme(s) other than cPKC but downstream of AKT.
Indeed, In vitro studies using recombinant peptides have suggested
that Go-6976 can interact with additional kinases, including p70
S6 kinase-1 [10], which we previously reported to be involved in
our model of insulin resistance [7]. We therefore next measured
the insulin-stimulated activation of S6 kinase-1 (i.e. pThr389-
S6K:Total S6K ratio) and the phosphorylation of its substrate, S6
ribosomal protein (on Ser 240/244). As reported previously [7],
acute insulin treatment of IS adipocytes markedly stimulated the
activation of S6 kinase (8–10-fold) and increased the expression of
phosphorylated S6 ribosomal protein (3–5-fold, Fig. 6A). In GI-
IR adipocytes, basal levels of active S6 kinase-1 and S6 ribosomal
protein phosphorylation was significantly elevated (Fig. 6B) and
Go-6976 treatment prevented direct correlation between active
S6K and phosphorylated S6 ribosomal protein (Fig. 6B).
However, insulin-stimulated activation of this pathway was
reduced in GI-IR adipocytes, and Go-6976 treatment further
reduced both active S6K and S6 ribosomal protein phosphory-
lation (Fig. 6C). These data suggest that p70 S6 kinase-1 is a
candidate target for Go-6976 action in adipocytes.
Raptor knock-down enhances insulin-stimulated glucose
transport in GI-IR adipocytes but is additive with Go-6976
Since S6K-1 is a downstream target of mTOR-associated
proteins such as raptor we next investigated whether insulin-
stimulated glucose transport was altered in our model when
Raptor was knocked-down. Raptor expression decreased by 76%
in the cells treated with siRNA for Raptor (Fig. 7A). In IS
adipocytes, insulin stimulated glucose transport was not signifi-
cantly different in the Raptor knock-down cells as compared to the
non-targeted controls (Fig. 7B). However, in GI-IR adipocytes,
insulin-stimulated glucose transport increased by 40% in the
Raptor-deficient cells, a significant effect (Fig. 7B, p,0.04). We
next compared the response to Go-6976 of glucose transport
between non-targeted and knock-down cells (Fig. 7C). In IS
adipocytes, there was no difference either in basal or acute insulin
stimulated glucose transport between control and Raptor deficient
Figure 5. The effect of PKCl knock-down on hyperglycemia-induced insulin resistance. A. Western blot showing depletion (by 84%) of
PKCl in cells treated with anti-PKCl siRNA as compared to cells treated with NT control RNA. B. cells preincubated in 5 mM glucose (IS) vs. 25 mM
glucose+0.6 nM insulin (GI-IR) and then stimulated (the black bars) or not (basal) with acute, 100 nM insulin. Knock-down of PKCl mRNA decreased
the insulin-stimulation of glucose transport by ,20%, in IS adipocytes, but had no additional effect in GI-IR adipocytes. (*p,0.001, n = 15).
doi:10.1371/journal.pone.0108963.g005
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cells and the addition of 1 mM Go-6976 also had no effect.
However, in GI-IR adipocytes, Go-6976 significantly increased
insulin-stimulated glucose transport in the non-targeted cells (p,
0.03) but was unable to further improve glucose transport in
Raptor knock-down cells (Fig. 7C). Again, without Go-6976
treatment the insulin-stimulated glucose transport was greater (p,
0.005) in the Raptor knock-down cells than in the non-targeted
controls (Fig. 7C). These data suggest that the mTORC1
pathway indeed plays an important role in GI-IR adipocytes
and that Go-6976 alleviates this by targeting inhibition of
mTORC1 dependent pathway(s).
In summary, the major message of this paper is that the
mTORC1 pathway does play a role in eliciting high glucose/low
dose insulin mediated insulin resistance (GI-IR) in cultured
adipocytes, while we were unable to detect any significant role
of cPKC with the methods used here. This is important, because
cPKCs are thought to be important mediators of hyperglycemia-
associated pathology and experiments with the widely used cPKC
inhibitor Go-6976 initially suggested that cPKC-s might play a
major role in high glucose-induced insulin resistance in adipocytes.
However, our data clearly indicate that Go-6976 exerts its major
effects by inhibiting mTORC1 dependent pathways in the GI-IR
adipocytes. It is worth noting that this study has focused on one in
vitro model of hyperglycemia-induced insulin resistance in murine
adipocytes. As such, our findings do not rule out the possibility that
other PKC’s, novel or atypical, may play a role in the development
Figure 6. Effect of Go-6976 on S6 Kinase activity. Adipocytes were preincubated for 18 h in 5 mM glucose (IS) or in 25 mM glucose+0.6 nM
insulin (GI-IR). A. Acute insulin treatment (100 nM for 15 min) stimulated activating phosphorylation of S-6 kinase (8–10-fold) and of its substrate S-6
ribosomal protein (4–5-fold). Under basal conditions, GI-IR adipocytes exhibited enhanced S6K phosphorylation. For quantification purposes,
unstimulated (B) and acute insulin-stimulated (C) samples were also analysed on separate gels with exposure to times adjusted to within linear
ranges. Under these conditions it is evident that the acute insulin stimulated S6K activity was decreased in the GI-IR cells. This was further reduced by
treatment with Go-6976 (1 mM for 1 h). Statistical significance is indicated by *p,0.05 vs. control without Go-6976, **p,0.001. n = 9.
doi:10.1371/journal.pone.0108963.g006
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of insulin resistance induced by other mediators on in other
cellular systems. Indeed, there is ample evidence that lipid/FFA-
induced insulin resistance is associated with activation of PKChin
rodent skeletal muscle and PKCd and -b in human muscle.
Furthermore, in liver lipid-induced insulin resistance has been
linked to PKCe activity (reviewed in [18]). Hence, additional
studies are warranted before a significant clinical impact can be
assigned to our findings. Such studies should elucidate the
molecular target of Go-6976 action and confirm that similar
therapeutic effects also occur in human adipocytes and other
insulin target tissues. Such mechanistic insights will be crucial in
informing future targeted therapeutics aimed at treating patients
with hyperglycemia and IR while avoiding unanticipated side
effects.
Nonetheless, our findings highlight the fact that caution should
be exercised when interpreting mechanistic data from pharmaco-
logical studies alone because potentially misleading conclusions
can be drawn from use of very modest doses a ‘specific’
pharmacological inhibitor in cultured cells. That Go-6976 may
not be as specific as advertised has been reported previously,
where its inhibition of recombinant S6 kinase 1 has been
demonstrated [10]. By combining both targeted pharmaceuticals
with specific gene modulation we have demonstrated that a more
reliable and powerful approach can be taken to dissect complex
signaling pathways.
Supporting Information
Figure S1 Phosphorylated PKCalpha and total PKCal-
pha are not altered by hyperglycemia-induced insulin
resistance. Adipocytes were treated as described for Figure 3.
Figure 7. Raptor knock-down enhances the effect of insulin on glucose transport in insulin resistant cells. A Raptor expression was
decreased by 76% in adipocytes treated with anti-Raptor siRNA compared to cells treated with NT RNA. B Insulin-stimulated glucose transport is
enhanced by ,40% in hyperglycemia-induced insulin resistant (GI-IR) Raptor knock-down cells (* = p,0.005 vs. NT). C Go-6976 enhances insulin
stimulated glucose transport only in the insulin resistant NT cells (* = p,0.03), but not in the Raptor knock-down cells.
doi:10.1371/journal.pone.0108963.g007
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Representative western blots are shown for basal (A) and Insulin
stimulated (B) samples. Quantification is shown in Figure 3.
(PDF)
Figure S2 The PKCbeta inhibitor, Ruboxistaurin does
not affect insulin resistance in 3T3-L1 adipocytes. Cells
were preincubated in 5 mM glucose (IS) or in 25 M glucose+
0.6 nM insulin (GI-IR) and then acutely stimulated with (the black
bars) or without (the white bars) 100 nM insulin for 15 min. Some
samples were also supplemented with 300 nM Ruboxistaurin
(Rbxn) for 18 h or for 2 h, before insulin stimulation. Rubox-
istaurin did not affect insulin stimulation of glucose transport
under any of the conditions tested (n = 6).
(PDF)
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